Physician profile
Amanda Deen
NPI 1437643517
$1,783.15
in general payments reported to CMS, 2019-2025
17 companies · $694 in 2025
The $694 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.77 · 2022: $102 · 2023: $449 · 2024: $455 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $238.33 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Dexcom, INC. | $162.05 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.25 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $135.80 | 2021-2025 | Wegovy, Rybelsus |
| Lilly USA, LLC | $133.34 | 2023-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $43.51 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.40 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $23.85 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $20.74 | 2025 | |
| Lundbeck LLC | $20.72 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $19.87 | 2023 | Jynarque |
| Vanda Pharmaceuticals INC. | $19.52 | 2025 | Fanapt |
| Antares Pharma, INC. | $17.98 | 2025 | Xyosted |
| Horizon Therapeutics Plc | $17.32 | 2023 | Krystexxa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $14.94 | 2025 | Via Matrix |
| Glaxosmithkline, LLC. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Deen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.